Tsisia Kakhadze

Specialty: Radiology, Nuclear Medicine.

Professional activity:

Since 2010, radiologist “University Clinic of High Medical Technologies”

Head of the Department of Nuclear Medicine since 2012 IAEA certified doctor since 2013

Since 2014, doctor-radiologist of the Department of Radiation Oncology, University Clinic of High Medical Technologies. PET/CT

From 2021, doctor “University Clinic of Innovative Medicine – Department of Nuclear Medicine. PET/CT Radiologist from 2023 – “Alexandre Aladashvili Clinic”

2024 – K. Mardaleishvili Medical Center – PET/CT

Education

2008-2010- Residency Program in Medical Radiology “Acad. F. Todua Medical Center” 2003-2007 – Tbilisi State Medical University. Faculty of Medicine. Graduated physician. 2000-2003 – State Medical University College

1991-2000- 55 secondary schools in Tbilisi Qualification:

2011 – Lifemed – Department of Nuclear Medicine – Istanbul, Turkey.

2012-2013: Maria Sklodowska-Curie National Research Institute of Oncology – Department of Nuclear Medicine – Warsaw, Poland

2021: Policlinico Di Sant’ Orsola – Malpighi – Department of Nuclear Medicine – Bologna, Italy

Trainings:

2021- City Cancer Challenge – Harmonization, the Quality of Diagnostic Imaging for Cancer Care – Italy 2014- IAEA, Regional Training Course on Hybrid imaging: SPECT/CT and PET/CT- Parnu, Estonia 2014-Baltic Congress of Radiology

2014-ESNM, Advanced Learning Course on PET/CT in Oncology – Vienna, Austria 2008 – ECR Congress Vienna, Austria

2010-RSNA Congress of Radiologists, Chicago, USA 2013-RSNA Congress of Radiologists, Chicago, USA

Clinical studies:

2014 – A Phase 3, Randomized, Double-Blind Study of PF-05280586 Versus Rituximab for the First-Line Treatment of Patients with CD20-

Positive, Low Tumor Burden, Follicular Lymphoma – BioClinica Pfizer.

2023- A phase 3 (pivotal stage) study of NBTXR3 activated by investigator’s choice of radiotherapy alone or combination with Cetuximab for platinum-based chemotherapy-ineligible elderly patient with locally advanced Head & Neck squamous Cell Carcinoma. NANORAY-312